Deciphera Announces Multiple Data Presentations at the Connective Tissue Oncology Society (CTOS) Annual Meeting 2025

Core Insights - Ono Pharmaceutical Co., Ltd. announced the presentation of data from multiple pipeline programs, including long-term and safety results from the MOTION Phase 3 study of vimseltinib for patients with TGCT where surgical removal is not an option [1] Group 1 - The MOTION Phase 3 study results will be presented at the CTOS Annual Meeting 2025, scheduled for November 12-15 in Boca Raton, Florida [1]